Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type

R. Suzuki, J. Suzumiya, M. Yamaguchi, S. Nakamura, J. Kameoka, H. Kojima, M. Abe, T. Kinoshita, Tadashi Yoshino, K. Iwatsuki, Y. Kagami, T. Tsuzuki, M. Kurokawa, K. Ito, K. Kawa, K. Oshimi

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Background: Patients with natural killer (NK) cell neoplasms, aggressive NK cell leukemia (ANKL) and extranodal NK cell lymphoma, nasal type (ENKL), have poor outcome. Both diseases show a spectrum and the boundary of them remains unclear. The purpose of this study is to draw a prognostic model of total NK cell neoplasms. Patients and methods: We retrospectively analyzed 172 patients (22 with ANKL and 150 with ENKL). The ENKLs consisted of 123 nasal and 27 extranasal (16 cutaneous, 9 hepatosplenic, 1 intestinal and 1 nodal) lymphomas. Results: Complete remission rate for ENKL was 73% in stage I, but 15% in stage IV, which was consistent with that for ANKL (18%). The prognosis of ENKL was better than that of ANKL (median survival 10 versus 1.9 months, P <0.0001) but was comparable when restricted to stage IV cases (4.0 months, P = 0.16). Multivariate analysis showed that four factors (non-nasal type, stage, performance status and numbers of extranodal involvement) were significant prognostic factors. Using these four variables, an NK prognostic index was successfully constructed. Four-year overall survival of patients with zero, one, two and three or four adverse factors were 55%, 33%, 15% and 6%, respectively. Conclusion: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes.

Original languageEnglish
Pages (from-to)1032-1040
Number of pages9
JournalAnnals of Oncology
Volume21
Issue number5
DOIs
Publication statusPublished - Oct 22 2009

Fingerprint

Large Granular Lymphocytic Leukemia
Nose
Natural Killer Cells
Lymphoma
Neoplasms
Survival
Multivariate Analysis
Skin

Keywords

  • CD16
  • Leukemia
  • Lymphoma
  • Natural killer cell
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Prognostic factors for mature natural killer (NK) cell neoplasms : aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. / Suzuki, R.; Suzumiya, J.; Yamaguchi, M.; Nakamura, S.; Kameoka, J.; Kojima, H.; Abe, M.; Kinoshita, T.; Yoshino, Tadashi; Iwatsuki, K.; Kagami, Y.; Tsuzuki, T.; Kurokawa, M.; Ito, K.; Kawa, K.; Oshimi, K.

In: Annals of Oncology, Vol. 21, No. 5, 22.10.2009, p. 1032-1040.

Research output: Contribution to journalArticle

Suzuki, R, Suzumiya, J, Yamaguchi, M, Nakamura, S, Kameoka, J, Kojima, H, Abe, M, Kinoshita, T, Yoshino, T, Iwatsuki, K, Kagami, Y, Tsuzuki, T, Kurokawa, M, Ito, K, Kawa, K & Oshimi, K 2009, 'Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type', Annals of Oncology, vol. 21, no. 5, pp. 1032-1040. https://doi.org/10.1093/annonc/mdp418
Suzuki, R. ; Suzumiya, J. ; Yamaguchi, M. ; Nakamura, S. ; Kameoka, J. ; Kojima, H. ; Abe, M. ; Kinoshita, T. ; Yoshino, Tadashi ; Iwatsuki, K. ; Kagami, Y. ; Tsuzuki, T. ; Kurokawa, M. ; Ito, K. ; Kawa, K. ; Oshimi, K. / Prognostic factors for mature natural killer (NK) cell neoplasms : aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. In: Annals of Oncology. 2009 ; Vol. 21, No. 5. pp. 1032-1040.
@article{d0f0268d920246e08987091e3967e36c,
title = "Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type",
abstract = "Background: Patients with natural killer (NK) cell neoplasms, aggressive NK cell leukemia (ANKL) and extranodal NK cell lymphoma, nasal type (ENKL), have poor outcome. Both diseases show a spectrum and the boundary of them remains unclear. The purpose of this study is to draw a prognostic model of total NK cell neoplasms. Patients and methods: We retrospectively analyzed 172 patients (22 with ANKL and 150 with ENKL). The ENKLs consisted of 123 nasal and 27 extranasal (16 cutaneous, 9 hepatosplenic, 1 intestinal and 1 nodal) lymphomas. Results: Complete remission rate for ENKL was 73{\%} in stage I, but 15{\%} in stage IV, which was consistent with that for ANKL (18{\%}). The prognosis of ENKL was better than that of ANKL (median survival 10 versus 1.9 months, P <0.0001) but was comparable when restricted to stage IV cases (4.0 months, P = 0.16). Multivariate analysis showed that four factors (non-nasal type, stage, performance status and numbers of extranodal involvement) were significant prognostic factors. Using these four variables, an NK prognostic index was successfully constructed. Four-year overall survival of patients with zero, one, two and three or four adverse factors were 55{\%}, 33{\%}, 15{\%} and 6{\%}, respectively. Conclusion: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes.",
keywords = "CD16, Leukemia, Lymphoma, Natural killer cell, Prognosis",
author = "R. Suzuki and J. Suzumiya and M. Yamaguchi and S. Nakamura and J. Kameoka and H. Kojima and M. Abe and T. Kinoshita and Tadashi Yoshino and K. Iwatsuki and Y. Kagami and T. Tsuzuki and M. Kurokawa and K. Ito and K. Kawa and K. Oshimi",
year = "2009",
month = "10",
day = "22",
doi = "10.1093/annonc/mdp418",
language = "English",
volume = "21",
pages = "1032--1040",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Prognostic factors for mature natural killer (NK) cell neoplasms

T2 - aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type

AU - Suzuki, R.

AU - Suzumiya, J.

AU - Yamaguchi, M.

AU - Nakamura, S.

AU - Kameoka, J.

AU - Kojima, H.

AU - Abe, M.

AU - Kinoshita, T.

AU - Yoshino, Tadashi

AU - Iwatsuki, K.

AU - Kagami, Y.

AU - Tsuzuki, T.

AU - Kurokawa, M.

AU - Ito, K.

AU - Kawa, K.

AU - Oshimi, K.

PY - 2009/10/22

Y1 - 2009/10/22

N2 - Background: Patients with natural killer (NK) cell neoplasms, aggressive NK cell leukemia (ANKL) and extranodal NK cell lymphoma, nasal type (ENKL), have poor outcome. Both diseases show a spectrum and the boundary of them remains unclear. The purpose of this study is to draw a prognostic model of total NK cell neoplasms. Patients and methods: We retrospectively analyzed 172 patients (22 with ANKL and 150 with ENKL). The ENKLs consisted of 123 nasal and 27 extranasal (16 cutaneous, 9 hepatosplenic, 1 intestinal and 1 nodal) lymphomas. Results: Complete remission rate for ENKL was 73% in stage I, but 15% in stage IV, which was consistent with that for ANKL (18%). The prognosis of ENKL was better than that of ANKL (median survival 10 versus 1.9 months, P <0.0001) but was comparable when restricted to stage IV cases (4.0 months, P = 0.16). Multivariate analysis showed that four factors (non-nasal type, stage, performance status and numbers of extranodal involvement) were significant prognostic factors. Using these four variables, an NK prognostic index was successfully constructed. Four-year overall survival of patients with zero, one, two and three or four adverse factors were 55%, 33%, 15% and 6%, respectively. Conclusion: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes.

AB - Background: Patients with natural killer (NK) cell neoplasms, aggressive NK cell leukemia (ANKL) and extranodal NK cell lymphoma, nasal type (ENKL), have poor outcome. Both diseases show a spectrum and the boundary of them remains unclear. The purpose of this study is to draw a prognostic model of total NK cell neoplasms. Patients and methods: We retrospectively analyzed 172 patients (22 with ANKL and 150 with ENKL). The ENKLs consisted of 123 nasal and 27 extranasal (16 cutaneous, 9 hepatosplenic, 1 intestinal and 1 nodal) lymphomas. Results: Complete remission rate for ENKL was 73% in stage I, but 15% in stage IV, which was consistent with that for ANKL (18%). The prognosis of ENKL was better than that of ANKL (median survival 10 versus 1.9 months, P <0.0001) but was comparable when restricted to stage IV cases (4.0 months, P = 0.16). Multivariate analysis showed that four factors (non-nasal type, stage, performance status and numbers of extranodal involvement) were significant prognostic factors. Using these four variables, an NK prognostic index was successfully constructed. Four-year overall survival of patients with zero, one, two and three or four adverse factors were 55%, 33%, 15% and 6%, respectively. Conclusion: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes.

KW - CD16

KW - Leukemia

KW - Lymphoma

KW - Natural killer cell

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=77953227669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953227669&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp418

DO - 10.1093/annonc/mdp418

M3 - Article

C2 - 19850638

AN - SCOPUS:77953227669

VL - 21

SP - 1032

EP - 1040

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -